Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH. The company was founded in 2008 and is headquartered in Livonia, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GEMP
CUSIPN/A
Phone734-245-1700
Debt
Debt-to-Equity Ratio0.37
Current Ratio5.57
Quick Ratio5.57
Price-To-Earnings
Trailing P/E Ratio-2.22
Forward P/E Ratio-2.79
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.37 per share
Price / Book19.41
Profitability
EPS (Most Recent Fiscal Year)($3.23)
Net Income$-33,410,000.00
Net MarginsN/A
Return on Equity-233.06%
Return on Assets-118.56%
Miscellaneous
Employees18
Outstanding Shares14,230,000
Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions
What is Gemphire Therapeutics' stock symbol?
Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."
How were Gemphire Therapeutics' earnings last quarter?
Gemphire Therapeutics Inc (NASDAQ:GEMP) released its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.58) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.63) by $0.05. View Gemphire Therapeutics' Earnings History.
When is Gemphire Therapeutics' next earnings date?
What price target have analysts set for GEMP?
6 Wall Street analysts have issued twelve-month price targets for Gemphire Therapeutics' stock. Their predictions range from $18.00 to $31.00. On average, they expect Gemphire Therapeutics' stock price to reach $25.1667 in the next twelve months. View Analyst Ratings for Gemphire Therapeutics.
What are Wall Street analysts saying about Gemphire Therapeutics stock?
Here are some recent quotes from research analysts about Gemphire Therapeutics stock:
- 1. According to Zacks Investment Research, "Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. " (3/21/2018)
- 2. Canaccord Genuity analysts commented, "We believe gemcabene’s 40% hsCRP reduction is very meaningful, especially given that Novartis canikinumab reduced hsCRP and lowered Major Adverse Cardiac Events (MACE). In our view, gemcabene has lowering effects on important biomarkers beyond LDL, including triglycerides and hsCRP, differentiating the drug from competitors. Continue to anticipate positive INDIGO-1 data in 2018 We expect gemcabene to show a statistically significant reduction in triglycerides in the INDIGO-1 study in 2018, providing a major catalyst for shares to move higher. Importantly, many drugs can lower LDL cholesterol, but some have no effect on triglycerides, such as PCSK9 therapies." (10/13/2017)
Who are some of Gemphire Therapeutics' key competitors?
Some companies that are related to Gemphire Therapeutics include Achillion Pharmaceuticals (ACHN), Savara (SVRA), American Brivision (Holding) (ABVC), Albireo Pharma (ALBO), Unum Therapeutics (UMRX), Bellicum Pharmaceuticals (BLCM), Evelo Biosciences (EVLO), Arbutus Biopharma (ABUS), Corvus Pharmaceuticals (CRVS), Aquinox Pharmaceuticals (AQXP), Axovant Sciences (AXON), Catalyst Pharmaceuticals (CPRX), Seres Therapeutics (MCRB), DURECT (DRRX) and Minerva Neurosciences (NERV).
Who are Gemphire Therapeutics' key executives?
Gemphire Therapeutics' management team includes the folowing people:
- Dr. Charles L. Bisgaier Ph.D., Co-Founder, Chairman and Chief Scientific Officer (Age 64)
- Dr. Steven R. Gullans, Interim Chief Exec. Officer, Interim Pres & Director (Age 65)
- Mr. Jeffrey S. Mathiesen, Chief Financial Officer and Sec. (Age 57)
- Mr. Seth Reno MBA, Chief Commercial Officer (Age 51)
- Dr. Lee Golden M.D., Chief Medical Officer (Age 50)
When did Gemphire Therapeutics IPO?
(GEMP) raised $30 million in an IPO on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.
Has Gemphire Therapeutics been receiving favorable news coverage?
Headlines about GEMP stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a coverage optimism score of 0.14 on Accern's scale. They also gave news headlines about the company an impact score of 46.91 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Gemphire Therapeutics' major shareholders?
Gemphire Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Exchange Capital Management Inc. (3.77%), Bamco Inc. NY (3.59%), Sphera Funds Management LTD. (3.38%), Highland Capital Management LP (0.76%), DAFNA Capital Management LLC (0.70%) and Northern Trust Corp (0.21%). Company insiders that own Gemphire Therapeutics stock include Andy Sassine, David Lowenschuss, Jeffrey S Mathiesen, Mina Sooch and Steven R PhD Gullans. View Institutional Ownership Trends for Gemphire Therapeutics.
Which major investors are buying Gemphire Therapeutics stock?
GEMP stock was acquired by a variety of institutional investors in the last quarter, including Exchange Capital Management Inc., Sphera Funds Management LTD., Bamco Inc. NY, Highland Capital Management LP, DAFNA Capital Management LLC, Segall Bryant & Hamill LLC and Northern Trust Corp. Company insiders that have bought Gemphire Therapeutics stock in the last two years include Andy Sassine, David Lowenschuss, Jeffrey S Mathiesen, Mina Sooch and Steven R PhD Gullans. View Insider Buying and Selling for Gemphire Therapeutics.
How do I buy shares of Gemphire Therapeutics?
Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gemphire Therapeutics' stock price today?
One share of GEMP stock can currently be purchased for approximately $7.18.
How big of a company is Gemphire Therapeutics?
Gemphire Therapeutics has a market capitalization of $103.75 million. The company earns $-33,410,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Gemphire Therapeutics employs 18 workers across the globe.
How can I contact Gemphire Therapeutics?
Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]
MarketBeat Community Rating for Gemphire Therapeutics (GEMP)
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
